Cargando…

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC imp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cartin-Ceba, Rodrigo, Halank, Michael, Ghofrani, Hossein-Ardeschir, Humbert, Marc, Mattson, John, Fritsch, Arno, Krowka, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987907/ https://www.ncbi.nlm.nih.gov/pubmed/29565224 http://dx.doi.org/10.1177/2045894018769305

Ejemplares similares

Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
por: Stephan, Rosenkranz, et al.
Publicado: (2015)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
por: Humbert, Marc, et al.
Publicado: (2017)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
por: Thenappan, Thenappan, et al.
Publicado: (2020)

Outcomes of Liver Transplantation in Treated Portopulmonary Hypertension Patients With a Mean Pulmonary Arterial Pressure ≥35 mm Hg
por: DuBrock, Hilary M., et al.
Publicado: (2020)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

The molecular targets of approved treatments for pulmonary arterial hypertension
por: Humbert, Marc, et al.
Publicado: (2016)

The role of combination therapy in managing pulmonary arterial hypertension
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2014)

Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis
por: Krowka, Michael, et al.
Publicado: (2020)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes
por: del Valle, Kathryn T., et al.
Publicado: (2022)

Portopulmonary hypertension
por: Saleemi, Sarfraz
Publicado: (2010)

Riociguat: PATENT-1 Study
por: Said, Karim
Publicado: (2014)

Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes
por: DuBrock, Hilary M., et al.
Publicado: (2019)

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
por: García Aguilar, Humberto, et al.
Publicado: (2022)

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
por: Wang, Chen, et al.
Publicado: (2016)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

Response to: Comment on “Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding”
por: Rai, Nabham, et al.
Publicado: (2018)

Portopulmonary Hypertension: An Updated Review
por: Jasso-Baltazar, Erick A., et al.
Publicado: (2023)

Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension
por: Wiedenroth, Christoph B., et al.
Publicado: (2018)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
por: Hoeper, Marius M., et al.
Publicado: (2017)

Left main coronary artery compression in a patient with portopulmonary hypertension
por: de Araújo, Iara Teixeira, et al.
Publicado: (2018)

Living donor liver transplantation in a patient with severe portopulmonary hypertension
por: Singh, Shweta A, et al.
Publicado: (2020)

Portopulmonary Hypertension: From Bench to Bedside
por: Thomas, Christopher, et al.
Publicado: (2020)

Causes and Circumstances of Death in Portopulmonary Hypertension
por: Sahay, Sandeep, et al.
Publicado: (2021)

Natural killer cell-mediated immune deficiency or compromise in patients with portopulmonary hypertension
por: Chen, Huisong, et al.
Publicado: (2014)

Portopulmonary hypertension: Success with combined medical treatment
por: Hernández, María, et al.
Publicado: (2023)

Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry
por: DuBrock, Hilary M., et al.
Publicado: (2021)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding
por: Rai, Nabham, et al.
Publicado: (2018)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Portopulmonary hypertension
por: Saleemi, Sarfraz, et al.
Publicado: (2014)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_su0c5a0lcme0n3plcracb6su4r